ABVC Total Liab vs Net Invested Capital Analysis

ABVC Stock

USD 1.36 0.00 0.00%

ABVC Biopharma financial indicator trend analysis is way more than just evaluating ABVC Biopharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ABVC Biopharma is a good investment. Please check the relationship between ABVC Biopharma Total Liab and its Net Invested Capital accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.

Total Liab vs Net Invested Capital

Total Liab vs Net Invested Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ABVC Biopharma Total Liab account and Net Invested Capital. At this time, the significance of the direction appears to have strong relationship.

The correlation between ABVC Biopharma's Total Liab and Net Invested Capital is 0.69. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Net Invested Capital in the same time period over historical financial statements of ABVC Biopharma, assuming nothing else is changed. The correlation between historical values of ABVC Biopharma's Total Liab and Net Invested Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of ABVC Biopharma are associated (or correlated) with its Net Invested Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Invested Capital has no effect on the direction of Total Liab i.e., ABVC Biopharma's Total Liab and Net Invested Capital go up and down completely randomly.

Correlation Coefficient

0.69

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Net Invested Capital

The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.

Most indicators from ABVC Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ABVC Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.As of April 29, 2024, Selling General Administrative is expected to decline to about 5 M. In addition to that, Tax Provision is expected to decline to about 217.9 K

	2021	2022	2023	2024 (projected)
Other Operating Expenses	11.7M	16.1M	8.4M	4.2M
Total Revenue	355.8K	969.8K	152.4K	157.4K

Other Operating Expenses Total Revenue

ABVC Biopharma fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Other Current Liab	Current Deferred Revenue	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock	Net Receivables	Other Current Assets	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Common Stock Total Equity	Property Plant And Equipment Gross
Total Assets		0.64	0.73	0.91	0.16	-0.71	-0.04	0.16	0.51	0.79	0.78	0.67	0.58	0.62	0.64	-0.36	0.58	0.59	-0.46	0.81	0.52	0.79	0.86	0.01	-0.2	0.76
Short Long Term Debt Total	0.64		0.63	0.4	0.44	-0.31	-0.2	0.58	-0.19	0.32	0.81	0.65	0.82	0.37	0.07	-0.24	0.61	0.61	-0.26	0.69	0.75	0.24	0.41	0.03	-0.3	0.19
Total Current Liabilities	0.73	0.63		0.41	0.57	-0.62	-0.23	0.08	0.37	0.61	0.94	0.32	0.75	0.89	0.48	-0.26	0.2	0.21	-0.2	0.55	0.26	0.58	0.84	0.27	0.18	0.55
Total Stockholder Equity	0.91	0.4	0.41		-0.11	-0.64	0.08	0.05	0.57	0.75	0.45	0.62	0.32	0.33	0.67	-0.3	0.56	0.57	-0.5	0.73	0.44	0.79	0.7	-0.11	-0.37	0.76
Net Debt	0.16	0.44	0.57	-0.11		-0.24	-0.14	0.09	0.12	0.19	0.51	-0.32	0.62	0.36	0.2	0.06	-0.41	-0.41	-0.23	-0.01	-0.22	0.18	0.38	0.07	-0.08	0.18
Retained Earnings	-0.71	-0.31	-0.62	-0.64	-0.24		0.2	-0.16	-0.74	-0.99	-0.56	-0.31	-0.4	-0.51	-0.72	-0.16	-0.19	-0.2	0.32	-0.52	-0.13	-0.75	-0.71	-0.31	0.26	-0.74
Common Stock Shares Outstanding	-0.04	-0.2	-0.23	0.08	-0.14	0.2		-0.21	0.08	-0.15	-0.21	-0.06	-0.24	-0.13	-0.06	-0.25	-0.04	-0.04	-0.26	-0.07	-0.07	0.02	-0.03	0.04	-0.16	0.04
Non Current Liabilities Total	0.16	0.58	0.08	0.05	0.09	-0.16	-0.21		-0.41	0.13	0.34	0.44	0.25	-0.11	-0.13	0.42	0.52	0.51	-0.13	0.21	0.58	-0.06	-0.08	0.01	-0.17	-0.08
Inventory	0.51	-0.19	0.37	0.57	0.12	-0.74	0.08	-0.41		0.77	0.19	-0.07	-0.02	0.46	0.76	-0.05	-0.22	-0.21	-0.21	0.25	-0.36	0.74	0.68	0.18	-0.08	0.76
Other Stockholder Equity	0.79	0.32	0.61	0.75	0.19	-0.99	-0.15	0.13	0.77		0.57	0.37	0.39	0.51	0.77	0.08	0.26	0.27	-0.39	0.57	0.18	0.81	0.76	0.24	-0.29	0.8
Total Liab	0.78	0.81	0.94	0.45	0.51	-0.56	-0.21	0.34	0.19	0.57		0.51	0.75	0.82	0.4	-0.31	0.43	0.44	-0.22	0.64	0.5	0.54	0.78	0.24	0.09	0.5
Total Current Assets	0.67	0.65	0.32	0.62	-0.32	-0.31	-0.06	0.44	-0.07	0.37	0.51		0.41	0.23	-0.02	-0.3	0.96	0.96	-0.24	0.88	0.93	0.19	0.25	0.0	-0.22	0.13
Short Term Debt	0.58	0.82	0.75	0.32	0.62	-0.4	-0.24	0.25	-0.02	0.39	0.75	0.41		0.4	0.14	-0.1	0.3	0.31	-0.43	0.59	0.47	0.24	0.46	-0.01	-0.23	0.2
Other Current Liab	0.62	0.37	0.89	0.33	0.36	-0.51	-0.13	-0.11	0.46	0.51	0.82	0.23	0.4		0.49	-0.45	0.12	0.13	0.03	0.43	0.1	0.59	0.84	0.36	0.43	0.56
Current Deferred Revenue	0.64	0.07	0.48	0.67	0.2	-0.72	-0.06	-0.13	0.76	0.77	0.4	-0.02	0.14	0.49		-0.07	-0.02	-0.01	-0.23	0.18	-0.13	0.96	0.83	0.21	-0.14	0.98
Accounts Payable	-0.36	-0.24	-0.26	-0.3	0.06	-0.16	-0.25	0.42	-0.05	0.08	-0.31	-0.3	-0.1	-0.45	-0.07		-0.28	-0.28	-0.03	-0.37	-0.25	-0.23	-0.36	-0.04	-0.09	-0.19
Cash	0.58	0.61	0.2	0.56	-0.41	-0.19	-0.04	0.52	-0.22	0.26	0.43	0.96	0.3	0.12	-0.02	-0.28		1.0	-0.19	0.74	0.96	0.17	0.17	-0.02	-0.2	0.12
Cash And Short Term Investments	0.59	0.61	0.21	0.57	-0.41	-0.2	-0.04	0.51	-0.21	0.27	0.44	0.96	0.31	0.13	-0.01	-0.28	1.0		-0.2	0.74	0.95	0.18	0.17	-0.01	-0.2	0.13
Common Stock	-0.46	-0.26	-0.2	-0.5	-0.23	0.32	-0.26	-0.13	-0.21	-0.39	-0.22	-0.24	-0.43	0.03	-0.23	-0.03	-0.19	-0.2		-0.29	-0.19	-0.27	-0.28	0.47	0.29	-0.27
Net Receivables	0.81	0.69	0.55	0.73	-0.01	-0.52	-0.07	0.21	0.25	0.57	0.64	0.88	0.59	0.43	0.18	-0.37	0.74	0.74	-0.29		0.74	0.39	0.5	0.1	-0.31	0.33
Other Current Assets	0.52	0.75	0.26	0.44	-0.22	-0.13	-0.07	0.58	-0.36	0.18	0.5	0.93	0.47	0.1	-0.13	-0.25	0.96	0.95	-0.19	0.74		0.07	0.11	0.06	-0.29	0.01
Property Plant And Equipment Net	0.79	0.24	0.58	0.79	0.18	-0.75	0.02	-0.06	0.74	0.81	0.54	0.19	0.24	0.59	0.96	-0.23	0.17	0.18	-0.27	0.39	0.07		0.9	0.26	-0.18	1.0
Non Current Assets Total	0.86	0.41	0.84	0.7	0.38	-0.71	-0.03	-0.08	0.68	0.76	0.78	0.25	0.46	0.84	0.83	-0.36	0.17	0.17	-0.28	0.5	0.11	0.9		0.2	0.07	0.89
Non Currrent Assets Other	0.01	0.03	0.27	-0.11	0.07	-0.31	0.04	0.01	0.18	0.24	0.24	0.0	-0.01	0.36	0.21	-0.04	-0.02	-0.01	0.47	0.1	0.06	0.26	0.2		-0.1	0.25
Common Stock Total Equity	-0.2	-0.3	0.18	-0.37	-0.08	0.26	-0.16	-0.17	-0.08	-0.29	0.09	-0.22	-0.23	0.43	-0.14	-0.09	-0.2	-0.2	0.29	-0.31	-0.29	-0.18	0.07	-0.1		-0.18
Property Plant And Equipment Gross	0.76	0.19	0.55	0.76	0.18	-0.74	0.04	-0.08	0.76	0.8	0.5	0.13	0.2	0.56	0.98	-0.19	0.12	0.13	-0.27	0.33	0.01	1.0	0.89	0.25	-0.18

Click cells to compare fundamentals

ABVC Biopharma Account Relationship Matchups

ABVC Biopharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	6.9M	11.6M	13.7M	9.9M	14.9M	15.7M
Short Long Term Debt Total	4.6M	6.5M	3.1M	3.1M	2.5M	1.9M
Total Current Liabilities	6.8M	4.8M	3.7M	5.8M	5.9M	6.2M
Total Stockholder Equity	(151.0K)	3.4M	8.8M	3.1M	8.8M	9.3M
Net Debt	4.4M	2.2M	(2.7M)	3.0M	1.7M	1.8M
Retained Earnings	(15.9M)	(25.6M)	(38.5M)	(54.9M)	(65.4M)	(62.1M)
Common Stock Shares Outstanding	1.7M	2.0M	2.5M	3.2M	4.3M	4.6M
Liabilities And Stockholders Equity	6.9M	11.6M	13.7M	9.9M	14.9M	15.7M
Non Current Liabilities Total	238.4K	4.1M	1.1M	420.2K	429.1K	407.7K
Inventory	(477.0K)	(839.7K)	26.0K	1.3M	1.5M	1.6M
Other Stockholder Equity	15.0M	28.5M	46.8M	57.5M	73.7M	77.4M
Total Liab	7.1M	8.9M	4.8M	6.2M	6.4M	6.7M
Total Current Assets	878.2K	6.2M	9.6M	3.0M	1.7M	1.4M
Short Term Debt	4.3M	2.4M	2.0M	2.3M	2.0M	1.4M
Other Current Liab	2.4M	2.4M	1.7M	3.5M	3.7M	3.9M
Cash	144.3K	4.3M	5.8M	85.3K	716.8K	839.1K
Cash And Short Term Investments	144.3K	4.3M	5.9M	161.1K	796.1K	855.2K
Common Stock	19.5K	24.4K	28.9K	32.9K	7.9K	7.5K
Net Receivables	640.5K	999.4K	1.7M	1.4M	759.6K	625.0K
Other Current Assets	570.4K	1.7M	1.9M	150.2K	101.1K	96.0K
Non Current Assets Total	6.0M	5.4M	4.1M	6.9M	13.3M	14.0M
Non Currrent Assets Other	179.5K	164.8K	160.5K	1.3M	1.4M	1.5M
Common Stock Total Equity	213.7K	213.9K	19.5K	24.4K	28.1K	26.7K
Accumulated Other Comprehensive Income	663.8K	564.9K	539.7K	517.1K	516.4K	396.8K
Net Tangible Assets	(5.7M)	(151.0K)	3.4M	8.8M	10.2M	10.7M
Other Assets	1.4M	1.6M	2.0M	1.1M	1.3M	1.4M
Short Long Term Debt	4.0M	2.1M	1.8M	1.9M	1.5M	2.0M
Other Liab	27.5K	2.9K	19.3K	10.6K	12.2K	11.0K
Short Term Investments	3.4M	1.2M	108.1K	75.8K	79.3K	75.3K
Long Term Investments	3.4M	1.2M	932.8K	842.1K	2.5M	1.8M
Property Plant Equipment	510.1K	1.0M	2.3M	2.0M	2.3M	2.4M
Net Invested Capital	3.9M	8.1M	10.7M	5.0M	9.9M	10.3M
Net Working Capital	(5.9M)	1.3M	5.9M	(2.8M)	(4.3M)	(4.1M)
Capital Stock	19.5K	24.4K	28.9K	32.9K	7.9K	7.5K

Pair Trading with ABVC Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ABVC Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ABVC Biopharma will appreciate offsetting losses from the drop in the long position's value.

The ability to find closely correlated positions to ABVC Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ABVC Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ABVC Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ABVC Biopharma to buy it.

The correlation of ABVC Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ABVC Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ABVC Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for ABVC Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether ABVC Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ABVC Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abvc Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abvc Biopharma Stock:

How To Invest In ABVC

Details

Is ABVC Stock a good investment?

Details

What is ABVC Biopharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.

You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Complementary Tools for ABVC Stock analysis

When running ABVC Biopharma's price analysis, check to measure ABVC Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ABVC Biopharma is operating at the current time. Most of ABVC Biopharma's value examination focuses on studying past and present price action to predict the probability of ABVC Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ABVC Biopharma's price. Additionally, you may evaluate how the addition of ABVC Biopharma to your portfolios can decrease your overall portfolio volatility.

	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios

Is ABVC Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.43)

Revenue Per Share

0.035

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.43)

Return On Equity

(1.92)

The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ABVC Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ABVC Total Liab vs Net Invested Capital Analysis

Total Liab vs Net Invested Capital

Total Liab vs Net Invested Capital Correlation Analysis

Correlation Coefficient

Total Liab

Net Invested Capital

ABVC Biopharma fundamental ratios Correlations

ABVC Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ABVC Biopharma fundamental ratios Accounts

Pair Trading with ABVC Biopharma

Complementary Tools for ABVC Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 0.98	Current Deferred Revenue
Cash	+ 0.96	Total Current Assets
Cash And Short Term Investments	+ 0.96	Total Current Assets
Property Plant And Equipment Net	+ 0.96	Current Deferred Revenue

Other Stockholder Equity	- 0.99	Retained Earnings
Property Plant And Equipment Net	- 0.75	Retained Earnings
Property Plant And Equipment Gross	- 0.74	Retained Earnings
Inventory	- 0.74	Retained Earnings
Current Deferred Revenue	- 0.72	Retained Earnings
Non Current Assets Total	- 0.71	Retained Earnings